http://purl.org/np/RA17xaV0m-... RA17xaV0m-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-27T18:27:35.302Z

http://purl.org/np/RA17xaV0m-... RA17xaV0m-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

phentermine hydrochloride orally disintegrating tablets are sympathomimetic amine anorectic indicated as a short term adjunct a few weeks in a regimen of weight reduction based on exercise behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index greater than or equal to 3 kg m 2 2 1 the limited usefulness of agents of this class including phentermine hydrochloride should be measured against possible risk factors inherent in their use 1 phentermine hydrochloride orally disintegrating tablets are indicated as a short term a few weeks adjunct in a regimen of weight reduction based on exercise behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index greater than or equal to 3 kg m 2 2 below is a chart of body mass index bmi based on various heights and weights bmi is calculated by taking the patient s weight in kilograms kg divided by the patient s height in meters m squared metric conversions are as follows pounds 2 2 kg inches x 254 meters body mass index bmi kg m 2 header weight 5 5 3 5 6 5 9 6 6 3 14 27 25 23 21 19 18 15 29 27 24 22 2 19 16 31 28 26 24 22 2 17 33 3 28 25 23 21 18 35 32 29 27 25 23 19 37 34 31 28 26 24 2 39 36 32 3 27 25 21 41 37 34 31 29 26 22 43 39 36 33 3 28 23 45 41 37 34 31 29 24 47 43 39 36 33 3 25 49 44 4 37 34 31 the limited usefulness of agents of this class including phentermine hydrochloride see clinical pharmacology 12 1 12 2

Leoni Bücken

2021-06-27T18:27:35.302Z

http://purl.org/np/RA17xaV0m-... RA17xaV0m-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_9970 DOID_9970

Leoni Bücken

2021-06-27T18:27:35.302Z

http://purl.org/np/RA17xaV0m-... RA17xaV0m-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-27T18:27:35.302Z

http://purl.org/np/RA17xaV0m-... RA17xaV0m-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00191 drugbank:DB00191

Leoni Bücken

2021-06-27T18:27:35.302Z

http://purl.org/np/RA17xaV0m-... RA17xaV0m-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-27T18:27:35.302Z

http://purl.org/np/RA17xaV0m-... RA17xaV0m-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-27T18:27:35.302Z

http://purl.org/np/RA17xaV0m-... RA17xaV0m-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-06-27T18:27:35.302Z